ADPGK and neoplasm: The selected neoantigen Adpgk has not been shown to promote robust anti-tumor responses in earlier published studies29 using CpG as an adjuvant, interestingly we could confirm that the neoantigen delivered by BiA9*2_HF led to superior anti-tumor control and improved survival compared to a control CpG and peptide treated group (Fig. 8A, B).